Hepatitis B (HBV) vaccines

Hepatitis B (HBV) vaccines is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please log in or purchase a subscription.

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

Coronavirus COVID-19 (SARS-CoV-2)

COVID-19 December 2020 Update: Therapies and Vaccines

Moderna COVID-19 Vaccine

BNT162b2 COVID-19 Vaccine (BioNTech/Pfizer)

Managing Stress and Coping with COVID-19

Managing Sleep Problems during COVID-19

-- The first section of this topic is shown below --

VACCINE TYPE

Hepilsav-B: yeast-derived vaccine created with a novel adjuvant Toll-like receptor 9 (TLR9) agonist adjuvant
Recombivax HB: recombinant vaccine produced by Saccharomyces cerevisiae (baker’s yeast).
Engerix-B: recombinant vaccine, also produced by Saccharomyces cerevisiae.
Twinrix: bivalent vaccine providing protection against both hepatitis A and B: HAV (720 ELISA units/mL) and HBV (20mcg HBsAg/mL).
Comvax: bivalent vaccine providing protection against both Haemophilus influenzae type b and hepatitis B virus (no longer available in the U.S.)

-- To view the remaining sections of this topic, please log in or purchase a subscription --

VACCINE TYPE

Hepilsav-B: yeast-derived vaccine created with a novel adjuvant Toll-like receptor 9 (TLR9) agonist adjuvant
Recombivax HB: recombinant vaccine produced by Saccharomyces cerevisiae (baker’s yeast).
Engerix-B: recombinant vaccine, also produced by Saccharomyces cerevisiae.
Twinrix: bivalent vaccine providing protection against both hepatitis A and B: HAV (720 ELISA units/mL) and HBV (20mcg HBsAg/mL).
Comvax: bivalent vaccine providing protection against both Haemophilus influenzae type b and hepatitis B virus (no longer available in the U.S.)

There's more to see -- the rest of this entry is available only to subscribers.